Quantitative analysis for Century Therapeutics, Inc. (IPSC) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (31.0) (grade D). 25 signals analyzed (20 differentiated alt-data).
IPSC stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $2.27 | $2.16 | $2.20 |
| 2026-05-08 | $2.33 | $2.21 | $2.29 |
| 2026-05-20 | $2.26 | $2.12 | $2.25 |
| 2026-06-02 | $2.37 | $2.14 | $2.17 |
| 2026-06-12 | $2.28 | $2.18 | $2.25 |
| 2026-06-25 | $2.50 | $2.28 | $2.30 |
| 2026-07-08 | $2.44 | $2.28 | $2.43 |
| 2026-07-20 | $2.30 | $2.14 | $2.19 |
| 2026-07-30 | $2.21 | $2.02 | $2.19 |
| 2026-08-12 | $2.09 | $1.96 | $1.96 |
| 2026-08-24 | $2.14 | $2.03 | $2.12 |
| 2026-09-03 | $2.13 | $2.05 | $2.09 |
How Century Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc. | $194M | 66.0 |
| ACB | Aurora Cannabis Inc. | $197M | 35.0 |
| CRBU | Caribou Biosciences, Inc. | $198M | — |
| ALMR | Alamar Biosciences, Inc. | $189M | — |
View all Health Care stocks by valuation and signals →
Century Therapeutics, Inc. (IPSC) scores Sell (31.0), and the composite conceals a 57-point disagreement between its dimensions. It is strongest on analyst consensus at 82 and competitive moat at 67, and weakest on technicals at 25. A stock can carry analyst consensus that high while technicals sits at 25; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 82 |
| competitive moat | 67 |
| technicals | 25 |
StoQuant analyzes 25 signals (20 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Century Therapeutics, Inc. (IPSC): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IPSC"><img src="https://stoquant.com/badge/IPSC.svg" alt="Century Therapeutics, Inc. (IPSC) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.